Tirzepatide Microdose $45/12mg A gentle twice-weekly microdose of tirzepatide for a slower, lower-side-effect approach to dual-pathway GLP-1 support
It is entirely understandable to feel frustrated if existing treatments have not met your expectations
Across the European region, the prevalence of obesity is projected to be 29.42% in men and 29.97% in women in 2030, with an estimated 102 million men and 113 million women at risk of the complications of obesity
During eating windows, add healthy fats (avocado, olive oil) for sustained fullness
Recurring ones can have an impact on your diabetes management strategy, distracting your focus from your blood sugar levels or causing stress that can keep your blood sugar levels high
Patients who require GLP-1 medications often have underlying vascular and metabolic risk factors such as diabetes, obesity, and cardiovascular disease, which themselves increase the risk of ischemic optic neuropathy, Skondra explained